Abstract
Purpose
Alpelisib is a phosphoinositide-3-kinase inhibitor approved for hormone-receptor-positive, PIK3CA-mutated metastatic breast cancer. However, length of drug exposure, maximum-tolerated dose, and therefore clinical response can vary significantly outside of the trial setting. This study evaluates our center’s “real world” experience with alpelisib and focuses on duration of therapy and factors associated with cancer progression.
Methods
Patients receiving alpelisib at our center between 2019 and 2021 were identified. We evaluated duration of alpelisib therapy and the causative reasons for drug discontinuation. The association of drug duration and dose with subsequent cancer progression were assessed, along with the association between hyperglycemia during alpelisib therapy and cancer progression.
Results
Sixty-two women prescribed alpelisib were included (mean age 61 years). Disease progression was the most common reason for drug discontinuation, while discontinuation within 30 days was primarily attributed to adverse events (AEs). Among those who progressed, median time to progression was longer in those on alpelisib for > 90 days compared with those on alpelisib for ≤ 90 days (187 vs. 77 days, p < 0.001). At 200 days, freedom from progression was greater for those on alpelisib for > 90 days compared to those receiving therapy for ≤ 90 days (59% vs. 19%, p = 0.001). Median blood glucose as a continuous variable was associated with disease progression (HR 1.01, 95% CI 1.00–1.02, p = 0.02).
Conclusion
While progression of disease is the largest contributor to alpelisib discontinuation, AEs are the leading cause for early drug cessation. Shorter alpelisib exposure is associated with greater cancer progression. Further studies are needed to determine the impact of sustained hyperglycemia on cancer progression.
Similar content being viewed by others
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Code availability
All statistical methods and codes are available for review upon request.
References
André F, Ciruelos E, Rubovszky G et al (2019) Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 380:1929–1940
Rugo HS, André F, Yamashita T et al (2020) Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol 31:1001–1010
Juric D, Rodon J, Tabernero J et al (2018) Phosphatidylinositol 3-kinase α-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study. J Clin Oncol 36:1291–1299
Rugo HS, Lerebours F, Ciruelos E et al (2021) Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol 22:489–498
Brunello A, Kapoor R, Extermann M (2011) Hyperglycemia during chemotherapy for hematologic and solid tumors is correlated with increased toxicity. Am J Clin Oncol 34:299–306
Ahn HR, Kang SY, Youn HJ et al (2020) Hyperglycemia during adjuvant chemotherapy as a prognostic factor in breast cancer patients without diabetes. J Breast Cancer 23:398–409
Alenzi EO, Kelley GA (2017) The association of hyperglycemia and diabetes mellitus and the risk of chemotherapy-induced neutropenia among cancer patients: a systematic review with meta-analysis. J Diabetes Complications 31:267–272
Wu AH, Kurian AW, Kwan ML et al (2015) Diabetes and other comorbidities in breast cancer survival by race/ethnicity: the California breast cancer survivorship consortium (CBCSC). Cancer Epidemiol Biomarkers Prev 24:351–358
Rao Kondapally Seshasai S, Kaptoge S, Thompson A et al (2011) Emerging risk factors collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364:829–841
Chang YL, Sheu WH, Lin SY et al (2018) Good glycaemic control is associated with a better prognosis in breast cancer patients with type 2 diabetes mellitus. Clin Exp Med 18:383–390
Erickson K, Patterson RE, Flatt SW et al (2011) Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer. J Clin Oncol 29:54–60
Yoo JH, Choi MS, Ahn J et al (2020) Association between continuous glucose monitoring-derived time in range, other core metrics, and albuminuria in type 2 diabetes. Diabetes Technol Ther 22:768–776
Lu J, Ma X, Zhou J et al (2018) Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes. Diabetes Care 41:2370–2376
Mayeda L, Katz R, Ahmad I et al (2020) Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease. BMJ Open Diabetes Res Care 8:e000991
Lu J, Home PD, Zhou J (2020) Comparison of multiple cut points for time in range in relation to risk of abnormal carotid intima-media thickness and diabetic retinopathy. Diabetes Care 43:e99–e101
Lu J, Ma X, Shen Y et al (2020) Time in range is associated with carotid intima-media thickness in type 2 diabetes. Diabetes Technol Ther 22:72–78
Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509
Wang DG, Barrios DM, Blinder VS et al (2020) Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer. Breast Cancer Res Treat 183:227–237
Fruman DA, Chiu H, Hopkins BD et al (2017) The PI3K pathway in human disease. Cell 170:605–635
Brandão M, Caparica R, Eiger D et al (2019) Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors. Ann Oncol. https://doi.org/10.1093/annonc/mdz280
Hopkins BD, Pauli CDX, Wang DG et al (2018) Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature 560:499–503
Acknowledgements
There are no additional acknowledgements to disclose.
Funding
No funding was received for the conduction of this study.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Y-MC and GC. The first draft of the manuscript was written by Y-MC and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
SMT receives institutional research funding from AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Exelixis, Bristol-Myers Squibb, Eisai, Nanostring, Cyclacel, Odonate, and Seattle Genetics; has served as an advisor/consultant to AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Bristol-Myers Squibb, Eisai, Nanostring, Puma, Sanofi, Celldex, Paxman, Puma, Silverback Therapeutics, G1 Therapeutics, Gilead, AbbVie, Athenex, OncoPep, Outcomes4Me, Kyowa Kirin Pharmaceuticals, Daiichi-Sankyo, and Samsung Bioepsis Inc. All other authors have no funding or conflicts of interest to disclose.
Ethical approval
This study has been approved by the MassGeneralBrigham Institutional Review Board (IRB).
Informed consent
Given the retrospective and low risk nature of this study, formal participant consent and consent to publish was not required.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Cheung, YM.M., Cromwell, G.E., Tolaney, S.M. et al. Factors leading to alpelisib discontinuation in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative breast cancer. Breast Cancer Res Treat 192, 303–311 (2022). https://doi.org/10.1007/s10549-021-06476-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-021-06476-1